Skip to main content

Table 1 Characteristics of included studies

From: Effects of platelet concentrates on implant stability and marginal bone loss: a systematic review and meta-analysis

References

Country

Study design

Sample size

Sex

Age

Type of platelet concentrates

Method of application

Outcome

Result

Alhussaini et al. [6]

Iraq

CCTa (split mouth)

32

Female 59.4%

25–66, 48.6 ± 10.3

PRFb

PRF clot placed in the implant sites

Implant stability (ISQc)

There was no statistically significant difference at 6 months (P = 0.348) and 12 months (P = 0.642)

Boora et al. [25]

India

RCTd

20

Female 25.0%

18–33, 24.6

PRF

PRF membrane placed in the implant sites

MBLe

The MBL of the test group was significantly lower than that of the control group within 3 months

Diana et al. [42]

India

RCT

31

Female 41.9%

28.5

PRF

PRF membrane placed in the implant sites

Implant stability (ISQ)

There was no statistically significant difference at 3 months (P = 0.645)

Ergun et al. [41]

Turkey

CCT

32

Female 53.1%

44.2 ± 12.5

PRPf

Dipping the implant in PRP liquid before insertion

Injected into the implant socket

Implant stability (ISQ)

There was no statistically significant difference in all periods

Khan et al. [43]

India

RCT

17

Female 35.3%

NR

PRF

Dipping the implant in PRF liquid before insertion

PRF membrane placed in the implant sites

MBL

There was no statistically significant

Difference between the two groups at all follow-up intervals

Khan et al. [28]

Pakistan

RCT

12

NRg

NR

PRP

Injected into the implant socket

MBL

There was no statistically significant

Difference between the two groups at all follow-up intervals

Kundu et al. [17]

India

RCT

30

Female 56.7%

18–56, 33.93 ± 11.25

PRP

Dipping the implant in PRP liquid before insertion

Implant stability (PTVh), MBL

For PTV, there was no statistically significant difference at 1 month (P = 0.107) and 3 months (P = 0.153)

PRP had no significant effect on bone height changes at 1 month and 3 months (P > 0.05)

Monov et al. [40]

Austria

CCT (split mouth)

10

Female 60.0%

53–80, 67

PRP

Dipping the implant in PRP liquid before insertion

Injected into the implant socket

Implant stability (Hz)

Except for the first week, there was no statistically significant difference between the two sides (P > 0.05)

Öncü et al. [21]

Turkey

RCT

20

Female 30.0%

44.2 ± 12.5

PRF

Dipping the implant in PRF liquid before insertion

PRF membrane placed in the implant sites

Implant stability (ISQ)

ISQ in the test group was significantly higher than that in the control group at the end of the first week (P = 0.002) and the fourth week (P = 0.001)

Öncü et al. [22]

Turkey

RCT (split mouth)

26

Female 38.5%

40.2 ± 11.5

PRF

PRF membrane placed in the implant sites

Implant stability (PTV), MBL

Except for the third month, ISQ in the test side was significantly higher than that in the control side at 1 week and 1 month (P ≤ 0.002)

PRF can significantly reduce marginal bone resorption after at least one year (P ≤ 0.05)

Koyuncu et al. [16]

Turkey

CCT

12

Female 58.3%

53–86

CGFi

CGF membrane placed in the implant sites

Implant stability (ISQ)

There was no statistically significant

Difference between the two groups

After 1, 2, and 4 weeks (P > 0.050)

Pirpir et al. [1]

Turkey

RCT

12

Female 58.3%

20–68, 44

CGF

Dipping the implant in CGF liquid before insertion

CGF membrane placed in the implant sites

Implant stability (ISQ)

ISQ in the test group was significantly higher at week 1 and week 4 (P < 0.050)

Tabrizi et al. [23]

Iran

RCT (split mouth)

20

Female 55.0%

39.60 ± 6.74

PRF

PRF fibrin matrix placed in the implant sites

Implant stability (ISQ)

The PRF side got significantly higher ISQ at 2 weeks (P = 0.040), 4 weeks (P = 0.014), and 6 weeks (P = 0.027) after insertion

Torkzaban et al. [24]

Iran

CCT

10

Female 50.0%

26–60, 45.3

PRF

Dipping the implant in PRF liquid before insertion

PRF membrane placed in the implant sites

Implant stability (ISQ)

ISQ in the test group was significantly higher at the end of the first week (P = 0.004) and the first month (P = 0.015)

  1. aControlled clinical trial
  2. bPlatelet-rich fibrin
  3. cImplant stability quotient
  4. dRandomized controlled trial
  5. eMarginal bone loss
  6. fPlatelet-rich plasma
  7. gNot reported
  8. hPeriotest value
  9. iConcentrated growth factor